Simris Group confirms strategic direction and advances two amanitin-based ADC programs toward the clinic
Simris Group AB (publ) (“Simris” or the “Company”) confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in both liquid and solid tumors. Under strengthened specialist leadership, the Company will focus on advancing two proprietary Antibody-Drug Conjugate (“ADC”) programs into clinical development by late 2027 or early 2028.
